

AD_____

Award Number: W81XWH-04-1-0218

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

PRINCIPAL INVESTIGATOR: Linda A. deGraffenried, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas Health Science Center
San Antonio, TX 78229-3900

REPORT DATE: February 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-02-2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 JAN 2005 - 14 JAN 2006	
4. TITLE AND SUBTITLE Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0218	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Linda A. deGraffenried, Ph.D. E-mail: degraffenri@uthscsa.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas Health Science Center San Antonio, TX 78229-3900				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Our laboratory has been interested in the role of Akt in the development of hormone independent cancers. Using a breast cancer cell model, we previously demonstrated that tumors with a constitutively active Akt are resistant to anti-hormone therapy. In this study we have expanded upon our preliminary observations in the breast model into <i>in vitro</i> prostate cancer models to determine the molecular and biological mechanisms underlying these findings. In our second year of this study, we found that treatment with an Akt inhibitor prevented the progression of LNCaP cells to a state of androgen-independence. These results correlated with suppression of expression of the androgen receptor, as well as suppression of the pro-survival proteins bcl-2 and NF-kB. We are currently exploring the significance of these findings in relationship to the preventive properties of the omega-3 fatty acids. Currently, progression of prostate cancer to androgen independence remains the primary obstacle to improved survival with this disease. The results of our studies suggest that targeting the Akt pathway may provide a strategy for preventing progression, resulting in increased survival among patients with recurrent disease.					
15. SUBJECT TERMS AKT, HORMONE INDEPENDENCE, SIGNAL TRANSDUCTION					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	7
References	N/A
Appendices	N/A

INTRODUCTION

Our laboratory has been interested in the role of Akt in the development of hormone-independent cancers. Using a breast cancer cell model, we have demonstrated that tumors with a constitutively active Akt are resistant to anti-hormone therapy. In this study we will expand our preliminary observations in the breast model into *in vitro* and *in vivo* prostate cancer models and determine the molecular and biological mechanisms underlying these findings.

BODY:

Task 1: To determine whether the level of phospho-Akt within the tumor is a predictor of eventual development of hormone-refractory disease.

Perform immunohistochemical staining and analyses of paraffin-embedded core prostate biopsies from two cohorts of patients: 1) those that **did** develop hormone refractory metastatic disease and 2) those that **did not** develop hormone refractory metastatic disease

We are continuing to compile the biopsy samples that will be evaluated for this Specific Aim. Once we have finished collecting the samples we will initiate the immunohistochemical studies.

Task 2: To investigate in vitro whether Akt signaling is a critical component of one of the mechanisms by which prostate cancer progresses to a condition of hormone independence.

Culture LNCaP and CRW-R1 cells under conditions of hormone ablation with and without co-treatment with an Akt inhibitor

In the previous progress report, we presented the results of our hormone ablation studies, in which we found that treatment with the Akt inhibitor prevented the progression of LNCaP cells to a state of androgen-independence. As seen in **Fig. 1**, all but one of the clones exposed to the Akt inhibitor arrested by week 5, and

never recovered. Conversely, only seventeen (43%) of the clones in the charcoal-stripped alone group (CSS) continuously arrested. Fourteen (40%) of the clones in the CSS group arrested, but then recovered, suggesting that this subset is now hormone-independent. Approximately 13% (5 of 40) of the clones in the CSS group never arrested, suggesting *de novo* resistance.

Supplementation with the synthetic androgen R1881 decreased the percentage of clones that were continuously arrested compared to the CSS group, (only 28% compared to 43%), while increasing the number of clones that either recovered or continuously proliferated (18 (45%) and 10 (25%), respectively). In this current report, we present the results of our molecular analysis of these cells.




Fig. 1. LNCaP growth response to androgen-depletion. 40 LNCaP subclones were each grown long-term under conditions of androgen-depletion (CSS, blue), CSS media supplemented with the 1 nM of the synthetic, nonmetabolizable androgen R1881 (R1881, red), and CSS media supplemented with 10 μ M of the Akt inhibitor I (Akt I, yellow). Clones were assessed at weeks 5 and 10, and determined to be either arrested or proliferating at each point.

Evaluate cells for cell cycle, morphological, and molecular status

We have initiated studies investigating the molecular basis for results obtained with the hormone ablation study. By Western blot analysis, we evaluated the expression levels of a panel of proteins involved in cell cycle regulation and apoptosis, including cyclin D, p21 and p27. Surprisingly, we found no differences in the expression levels of these proteins (data not shown). Several studies have demonstrated an increase in expression of the androgen receptor (AR) at time of relapse, in both preclinical and patient samples. In agreement with these studies, we consistently observed an increase in AR expression levels in those clones that became hormone independent, compared to the levels observed in the controls (**Fig 2**, CS vs. Cont). Intriguingly, the clones exposed to the Akt inhibitor (Akt I) did not demonstrate this increase in AR levels, even though they were also grown in charcoal-stripped conditions. This was observed in all of the 14 hormone independent clones tested. We are currently conducting studies to determine whether suppression of AR expression is at the transcriptional or post-transcriptional level, and whether it is one of the key reasons that the Akt inhibitor-grown clones were unable to progress to hormone independence.

In addition to the changes in AR expression, we also observed that increased levels of the pro-survival protein, bcl-2, were not evident in the Akt I cells. As with the AR data, we are currently exploring the relevance of this observation in relationship to the efficacy of the Akt inhibitor at suppressing progression.




Fig. 2 Protein expression levels in selected LNCaP clones. Protein lysates from LNCaP clones for 10 weeks in complete serum (Cont), charcoal-stripped serum (CS) and CS with 10μM Akt inhibitor (Akt I) were analyzed by Western blot analysis for expression the androgen receptor (AR) and the pro-survival protein bcl-2 (Bcl-2). Actin was used as a loading control. Shown are examples of 14 clones examined.

In addition to the AR, several reports have suggested that NF-κB signaling is also critical for prostate cancer progression to hormone independence.




Fig. 3 NF-κB activity in LNCaP clones. LNCaP clones grown for 10 weeks in complete serum (Complete FBS, green bar), charcoal-stripped serum (CS, blue bar) and CS with 10μM Akt inhibitor (Akt I, yellow bar) were analyzed by luciferase assay for relative NF-κB activity using the 5X NF-κB luc reporter construct. All results were standardized to Renilla activity and are relative to results obtained in the CS clones. Shown is the combination of three independent experiments with 6 clones.

activity may be critical for progression to hormone independence, and suppression of Akt activity may block this increase in activity. We are currently undertaking further studies to address this question.

Finally, since Akt inhibition effectively prevented progression to hormone independence, we were also interested in assessing its efficacy at inhibiting proliferation in hormone-independent cells.

As seen in **Fig. 4**, we found that hormone-independent clones grown for 96 hours in either charcoal-stripped serum or charcoal-stripped serum supplemented with 1 μ M of the synthetic androgen R1881 demonstrated no significant difference in growth. Importantly, these same clones grown in the presence of 10 μ M of the Akt inhibitor demonstrated an almost 60% decrease in proliferation, as assessed by MTT analysis. These data strongly suggest that Akt activity is critical for continued proliferation/survival even once cells have proceeded to hormone independence, and that Akt remains a potential target for clinical intervention in the metastatic setting, even once the disease has relapsed.




Fig. 4 Growth of hormone-independent LNCaP cells. Hormone-independent LNCaP clones grown for 10 weeks in charcoal-stripped serum were assessed by MTT analysis for proliferation when grown for 96 hours in charcoal-stripped serum alone (CS, blue bar), or CS supplemented with 1 μ M of the synthetic androgen R1881 (R1881, pink bar), or 10 μ M of the Calbiochem Akt inhibitor (Akt I, yellow bar). Shown is the combination of 3 independent experiments done with 6 clones. All results are relative to those obtained with the CS.

Task 3: To investigate in vivo whether Akt signaling is a critical component of the mechanism by which prostate cancer progresses to a condition of hormone independence.

Initiate implantation of CWR22 tumor xenografts

Last year we reported that implantation of the CRW22 xenografts was to be initiated shortly. Unfortunately, the original cells that were implanted into the mice were not hormone dependent. None of the tumors regressed upon removal of the testosterone pellet. We obtained new cells from the Gregory laboratory, and after extensive *in vitro* and *in vivo* testing for hormone dependence, we are now ready to start the animal studies again.

Carry out treatment and tissue harvesting regimens

Molecular, immunohistochemical and cell cycle analyses of harvested tissues

Perform statistical analyses

KEY RESEARCH ACCOMPLISHMENTS:

- Development of several AR-positive hormone-independent prostate cancer LNCaP sublines
- Demonstration that inhibition of the Akt pathway results in suppression of expression and activity of key proteins involved in prostate cancer progression, including the androgen receptor, bcl-2 and NF- κ B.
- Demonstration that Akt inhibition may be a realistic target for therapeutic intervention for the treatment of hormone-independent disease.

REPORTABLE OUTCOMES:

The data was presented at the annual meeting of the American Institute for Cancer Research.

CONCLUSIONS:

As part of our on-going studies to better understand the role of the Akt kinase pathway in the progression of prostate cancer, we have found that treatment with an Akt inhibitor inhibited almost all progression to hormone independence in an *in vitro* model of androgen ablation. This was correlated with a suppression of expression and activity of key proteins involved in progression. These results suggest a critical role for Akt signaling in prostate cancer progression. The results of these *in vitro* studies will be confirmed using an animal model of prostate cancer progression in studies scheduled for the upcoming year.

The results of these studies could have a significant impact on clinical approaches for the treatment of recurrent prostate cancer. Currently, progression of prostate cancer to androgen independence remains the primary obstacle to improved survival with this disease. In order to improve overall survival, novel treatment strategies that are based upon specific molecular mechanisms that prolong the androgen-dependent state and that are useful for androgen-independent disease need to be identified. The results of our studies suggest that targeting the Akt pathway may provide such a strategy, resulting in increased survival among patients with recurrent disease.